LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with OncoDNA, the first company in Europe to provide personalized medicine in oncology based on the molecular analysis of each patient’s tumor. Under this agreement, N-of-One will provide the clinical interpretation for all of OncoDNA’s next-generation sequencing (NGS) and other molecular tests done for patients throughout Europe, the Middle East, and in other parts of the world. Financial terms of the agreement are not disclosed.
OncoDNA provides comprehensive tumor profiling services in order to assist medical doctors in their treatment choices and provide better monitoring of the evolution of patient tumors. The lab is led by a team of highly experienced experts in DNA sequencing and diagnostic analyses in oncology.
N-of-One’s clinical interpretation provides the relevant biological and clinical knowledge and insights related to the mutation profile of a tumor identified by sequencing linking this knowledge to relevant therapeutic strategies, including clinical trials.
“We selected N-of-One for their best-in-class clinical interpretation and their ability to integrate multiple types of molecular test results into a single clinical report with very fast turnaround times,” said Jean-Pol Detiffe, CEO of OncoDNA. “N-of-One’s clinical interpretation uniquely provides the clinician with actionable insights and knowledge that can be used at the point of care.”
“OncoDNA’s industry-leading, molecular diagnostic solutions, coupled with N-of-One’s deep expertise in clinical interpretation in oncology, will enable broader patient access worldwide to personalized cancer treatment in a scalable, cost-effective manner,” said Chris Cournoyer, CEO of N-of-One.
About OncoDNA SA
OncoDNA is a leading company based in Belgium specialised in the personalised analysis of tumour DNA. OncoDNA currently has two products OncoDEEP & OncoTRACE. OncoDNA’s aim is to provide medical innovations based on targeted sequencing or complete sequencing of tumour genomes, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of patient tumors. For more information, please visit www.oncodna.com.
About N-of-One
N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options. N-of-One’s team of experts has interpreted more than 7,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists and through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.
Contacts
The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com
Help employers find you! Check out all the jobs and post your resume.
